The FDA granted Priority Review to gepotidacin for the treatment of female adults and adolescents with uncomplicated UTI.

The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.

US FDA accepts for priority review GSK’s NDA for gepotidacin to treat uncomplicated urinary tract infections in female adults and adolescents: London, UK Thursday, October 17, 2 ...

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an ...

Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials26 March 2025 assigned as action ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics ...

GSK announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for gepotidacin, a first-in-class oral antibiotic, under priority review.

(Alliance News) - GSK PLC on Wednesday announced that the US Food & Drug Administration has accepted its New Drug Application for gepotidacin. The London-based biopharma company said the FDA has ...

Stocks were higher in London on Wednesday morning, as data showed that UK consumer price inflation fell in September to its lowest rate in more than three years, while producer prices decreased. In ...

Here is what you need to know at the London market open: FTSE 100: opened up 56.75 points, or 0.7%, at 8,306.03 Hang Seng: up 0.3% at 20,371.80 Nikkei 225: closed down 1.8% at 39,180.30 S&P/ASX 200: ...

Stock futures were pointing to a slightly higher start for London's top-flight index on Wednesday following the release of a weaker-than-expected reading on UK inflation.

GSK plc (GSK, GSK.L) announced the FDA has accepted the New Drug Application for gepotidacin, an oral antibiotic with a mechanism of ...